Ovarian cancer trials in Taiwan

In Taiwan 32 Also abroad 794

32 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Where
Taichung, Taipei
Age
18 years and over
People
420 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500
Phase 2Taking people
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Where
Changhua, Tainan, Taipei
Age
18 years and over
People
397 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06787612 · EU 2024-517806-27-00
Phase 3Taking people
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Where
Kaohsiung City, New Taipei City, Taichung, Tainan, Taipei, Taoyuan
Age
18 years and over
People
950 worldwide
Run by
AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00
Phase 3Taking people
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Where
Tainan
Age
18 years and over
People
802 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07776691 · EU 2025-524592-22-00
Phase 3Taking people
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Where
Kaohsiung Niao Sung Dist, Taichung, Tainan, Taipei, Taoyuan
Age
18 years and over
People
1,630 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00
Phase 1/2Taking people
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Where
Taipei
Age
18 years and over
People
605 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06843447 · EU 2024-514674-47-00
Phase 3Taking people
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
Where
Tainan
Age
18 years and over
People
646 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07743164 · EU 2025-525130-59-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Taipei
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Where
Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan City
Age
18 years and over
People
582 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00
Phase 2/3Taking people
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Where
Taichung, Tainan, Taipei, Taoyuan City
Age
18 years and over
People
860 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Taichung, Tainan, Taipei
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1/2Taking people
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Where
Kaohsiung City, New Taipei City, Taipei, Taoyuan
Age
18 years and over
People
862 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT05914116
Phase 3Taking people
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Where
Kaohsiung City, Taichung, Tainan, Taipei
Age
18 years and over
People
600 worldwide
Run by
AstraZeneca
See details and how to joinNCT07816666 · EU 2026-526776-23-00
Phase 1Taking people
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Where
Kaohsiung City, Taichung, Taipei, Taoyuan City
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Taichung, Tainan, Taipei, Taoyuan
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Where
Taichung, Tainan, Taipei, Taoyuan
Age
18 years and over
People
770 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00
Phase 1Taking people
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
Where
Taipei
Age
18 years and over
People
285 worldwide
Run by
AbbVie
See details and how to joinNCT07278336 · EU 2025-522209-40-00
Phase 3Taking people
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Where
Taichung, Tainan, Taipei, Taoyuan
Age
18 years and over
People
900 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00
Phase 1/2Taking people
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Where
Taichung, Tainan, Taipei
Age
18 years to 130 years
People
622 worldwide
Run by
AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Liou Ying Township, Taipei, Taoyuan
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
No phaseTaking people
Ovarian Cancer Identification on CT Using Deep Learning
Where
Taoyuan, Taoyuan City
Age
20 years and over
People
12,578
Run by
Chang Gung Memorial Hospital
See details and how to joinNCT06851429
Phase 3Taking people
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Where
Changhua, New Taipei City, Taichung, Tainan, Taipei, Taoyuan
Age
18 years and over
People
1,100 worldwide
Run by
AstraZeneca
See details and how to joinNCT07218809 · EU 2025-520466-22-00
Phase 1Taking people
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Where
Kaohsiung City, Taipei
Age
18 years and over
People
1,006 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00
Phase 1Taking people
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Where
New Taipei City, Tainan, Taipei
Age
18 years and over
People
694 worldwide
Run by
AbbVie
See details and how to joinNCT05005403